Scholars@Duke
Jeffrey William Shevach

Jeffrey William Shevach

Assistant Professor of Medicine
Medicine, Medical Oncology

Selected Publications

Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.

Journal Article JAMA Oncol · October 1, 2025 IMPORTANCE: Much of the understanding of cancer risk associated with rare pathogenic variants (RPVs) is derived from family-based studies or clinically ascertained samples, which may be limited by ascertainment and selection bias. OBJECTIVE: To quantify as ... Full text Open Access Link to item Cite

Genetics of prostate cancer.

Journal Article Clin Adv Hematol Oncol · May 2025 Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic variants throughout the genome. Only HOXB13 has been identified as a prostate ... Link to item Cite

Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.

Journal Article JCO Clin Cancer Inform · February 2025 PURPOSE: This study introduces an integrated approach using structured and unstructured data from an electronic health record to identify and characterize patient utilization of hereditary cancer genetic testing among patients with metastatic castration-re ... Full text Link to item Cite

Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer

Journal Article Journal of the National Cancer Center · January 1, 2025 Prostate cancer remains the second most common malignancy among men worldwide, with treatment paradigms evolving dramatically over the last two decades. Despite the longstanding efficacy of androgen deprivation therapy (ADT) and its combination with next-g ... Full text Cite

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.

Journal Article JAMA Oncol · September 1, 2024 IMPORTANCE: Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic ... Full text Link to item Cite

Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers.

Journal Article J Natl Compr Canc Netw · April 17, 2024 BACKGROUND: Germline genetic testing is a vital component of guideline-recommended cancer care for males with pancreatic, breast, or metastatic prostate cancers. We sought to determine whether there were racial disparities in germline genetic testing compl ... Full text Link to item Cite

On-Site Nurse-Led Cancer Genetics Program Increases Cancer Genetic Testing Completion in Black Veterans.

Journal Article JCO Oncol Pract · August 2023 PURPOSE: Telegenetics services can expand access to guideline-recommended cancer genetic testing. However, access is often not distributed equitably to all races and ethnicities. We evaluated the impact of an on-site nurse-led cancer genetics service in a ... Full text Open Access Link to item Cite

Risk Assessment and Considerations for Proper Management of Elderly Men with Advanced Prostate Cancer: A Systematic Review.

Journal Article Eur Urol Oncol · August 2020 CONTEXT: Treatment decisions for elderly men with prostate cancer are complicated by the intersection of competing risks of cancer, potential complications of treatment, and individual patients' comorbidities. OBJECTIVE: To perform a systematic review of d ... Full text Link to item Cite

Adverse Effects of Androgen Deprivation in Elderly Men with Prostate Cancer

Journal Article Current Geriatrics Reports · December 1, 2019 Purpose of Review: The purpose of this review is to summarize the key literature of complications and adverse effects experienced by elderly men undergoing androgen deprivation therapy for prostate cancer, as well as evidence-based strategies to manage the ... Full text Cite

Quality of Life-Focused Decision-Making for Prostate Cancer.

Journal Article Curr Urol Rep · August 29, 2019 PURPOSE OF REVIEW: Quality of life (QoL) outcomes have been reported in the literature and incorporated in decision-making in localized prostate cancer management for decades. Until recently, there was less emphasis on understanding the QoL effects of ther ... Full text Link to item Cite

Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?

Journal Article Eur Urol Focus · March 2019 CONTEXT: Androgen deprivation therapy (ADT) is the standard of care for men with metastatic hormone-sensitive prostate cancer (HSPC) and a potential treatment option in those with prostate-specific antigen relapse after local therapy. Based on promising bi ... Full text Link to item Cite

Adjuvant therapy in high-risk prostate cancer.

Journal Article Clin Adv Hematol Oncol · January 2019 Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in a ... Link to item Cite

Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma.

Journal Article Oral Oncol · November 2017 OBJECTIVES: To determine the prognostic utility of pathologic extracapsular extension (ECE) in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC). MATERIALS AND METHODS: Retrospective analysis was performed on patients who ... Full text Link to item Cite

Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.

Journal Article Curr Urol Rep · March 2015 Treatment of advanced prostate cancer has changed considerably in recent years, but the vast majority of advances have been made in patients with metastatic castration-resistant disease. There have been relatively fewer advances in the earlier, hormonally ... Full text Link to item Cite

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Journal Article Front Oncol · 2015 OBJECTIVE: To determine if a concurrent diagnosis of diabetes mellitus is associated with worse outcomes in advanced prostate cancer (PC). The effect diabetes may have on the progression of advanced PC is poorly understood. METHODS: Data on 148 advanced PC ... Full text Open Access Link to item Cite